Symbols / ORGO $2.24 +0.00% Organogenesis Holdings Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NCM
ORGO Chart
About

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Drug Manufacturers - Spe Market Cap 288.16M
Enterprise Value 408.16M Income 20.02M Sales 564.17M
Book/sh 2.36 Cash/sh 0.75 Dividend Yield —
Payout 0.00% Employees 854 IPO —
P/E 14.93 Forward P/E 7.72 PEG —
P/S 0.51 P/B 0.95 P/C —
EV/EBITDA 5.44 EV/Sales 0.72 Quick Ratio 3.13
Current Ratio 3.62 Debt/Eq 18.93 LT Debt/Eq —
EPS (ttm) 0.15 EPS next Y 0.29 EPS Growth 5.55%
Revenue Growth 78.10% Earnings 2026-05-07 ROA 6.43%
ROE 9.04% ROIC — Gross Margin 75.62%
Oper. Margin 28.91% Profit Margin 6.56% Shs Outstand 128.64M
Shs Float 57.98M Short Float 27.73% Short Ratio 16.55
Short Interest — 52W High 7.08 52W Low 2.21
Beta 1.48 Avg Volume 669.89K Volume 1.32M
Target Price $8.00 Recom Strong_buy Prev Close $2.24
Price $2.24 Change 0.00%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.00
Mean price target
2. Current target
$2.24
Latest analyst target
3. DCF / Fair value
$-7.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.24
Low
$8.00
High
$8.00
Mean
$8.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 reit BTIG Buy → Buy $8
2026-02-27 main BTIG Buy → Buy $8
2025-12-26 reit BTIG Buy → Buy $9
2025-12-15 reit BTIG Buy → Buy $9
2025-11-20 main BTIG Buy → Buy $9
2025-09-26 reit BTIG Buy → Buy $7
2025-08-08 main Cantor Fitzgerald Overweight → Overweight $9
2025-07-15 reit Cantor Fitzgerald Overweight → Overweight $7
2025-03-05 main Morgan Stanley Equal-Weight → Equal-Weight $6
2024-06-28 init Lake Street — → Buy $5
2024-03-01 reit Cantor Fitzgerald Overweight → Overweight $5
2024-02-07 init Cantor Fitzgerald — → Overweight $5
2023-12-27 main BTIG Buy → Buy $6
2023-11-14 main Morgan Stanley Equal-Weight → Equal-Weight $4
2023-08-11 main Morgan Stanley Equal-Weight → Equal-Weight $3
2023-08-10 main BTIG Buy → Buy $4
2023-06-15 init Morgan Stanley — → Equal-Weight $5
2023-05-24 up BTIG Neutral → Buy $10
2022-11-10 down BTIG Buy → Neutral —
2021-11-10 main SVB Leerink — → Outperform $20
News
RSS: Latest ORGO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-09 LEIBOWITZ ARTHUR S Director — 5,000 $2.68 $13,405
2026-03-09 DRISCOLL MICHAEL JOSEPH Director — 10,000 $2.67 $26,688
2026-02-18 GILLHEENEY GARY S. SR. Chief Executive Officer — 1,077,593 $0.00 $0
2026-02-18 GILLHEENEY GARY S. SR. Chief Executive Officer — 1,079,481 $0.00 $0
2026-02-18 FREEDMAN LORI Officer — 245,905 $0.00 $0
2026-02-18 FREEDMAN LORI Officer — 246,337 $0.00 $0
2026-02-18 LEIBOWITZ ARTHUR S Director — 48,828 $0.00 $0
2026-02-18 GIACOMIN JON L Director — 48,828 $0.00 $0
2026-02-18 BILBO PATRICK Chief Operating Officer — 259,549 $0.00 $0
2026-02-18 BILBO PATRICK Chief Operating Officer — 260,039 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
563.03
+16.80%
482.04
+11.29%
433.14
-3.94%
450.89
Operating Revenue
563.03
+16.80%
482.04
+11.29%
433.14
-3.94%
450.89
Cost Of Revenue
137.52
+18.82%
115.74
+8.70%
106.48
+1.39%
105.02
Reconciled Cost Of Revenue
137.52
+18.82%
115.74
+8.70%
106.48
+1.39%
105.02
Gross Profit
425.51
+16.16%
366.30
+12.14%
326.66
-5.56%
345.87
Operating Expense
369.64
+7.21%
344.78
+9.76%
314.13
-2.92%
323.57
Research And Development
44.54
-11.40%
50.27
+13.27%
44.38
+11.61%
39.76
Selling General And Administration
326.24
+10.77%
294.51
+9.18%
269.75
-4.95%
283.81
Other Operating Expenses
-1.14
—
—
—
Total Expenses
507.16
+10.13%
460.52
+9.49%
420.62
-1.86%
428.59
Operating Income
55.87
+159.64%
21.52
+71.80%
12.53
-43.84%
22.30
Total Operating Income As Reported
44.69
+3583.55%
-1.28
-110.24%
12.53
-43.84%
22.30
EBITDA
82.81
+243.44%
24.11
-33.08%
36.03
-10.64%
40.32
Normalized EBITDA
93.98
+100.34%
46.91
+30.20%
36.03
-10.64%
40.32
Reconciled Depreciation
26.94
+6.16%
25.37
+8.21%
23.45
+30.05%
18.03
EBIT
55.87
+4523.52%
-1.26
-110.04%
12.58
-43.56%
22.29
Total Unusual Items
-11.18
+50.99%
-22.80
0.00
0.00
Total Unusual Items Excluding Goodwill
-11.18
+50.99%
-22.80
0.00
0.00
Special Income Charges
-11.18
+50.99%
-22.80
0.00
0.00
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
11.18
-40.69%
18.84
0.00
0.00
Restructuring And Mergern Acquisition
—
—
—
0.00
Write Off
0.00
-100.00%
3.96
0.00
0.00
Net Income
37.03
+4201.05%
0.86
-82.59%
4.95
-68.16%
15.53
Pretax Income
46.97
+1773.32%
-2.81
-127.01%
10.39
-48.76%
20.28
Net Non Operating Interest Income Expense
2.28
+247.73%
-1.54
+29.50%
-2.19
-9.01%
-2.01
Interest Expense Non Operating
—
1.54
-29.50%
2.19
+9.01%
2.01
Net Interest Income
2.28
+247.73%
-1.54
+29.50%
-2.19
-9.01%
-2.01
Interest Expense
—
1.54
-29.50%
2.19
+9.01%
2.01
Interest Income Non Operating
2.28
—
—
—
Interest Income
2.28
—
—
—
Other Income Expense
-11.18
+50.92%
-22.78
-40066.67%
0.06
+538.46%
-0.01
Other Non Operating Income Expenses
-0.01
-125.00%
0.02
-64.91%
0.06
+538.46%
-0.01
Tax Provision
9.94
+370.94%
-3.67
-167.34%
5.45
+14.67%
4.75
Tax Rate For Calcs
0.00
+0.95%
0.00
+0.00%
0.00
-10.26%
0.00
Tax Effect Of Unusual Items
-2.37
+50.52%
-4.79
0.00
0.00
Net Income Including Noncontrolling Interests
37.03
+4201.05%
0.86
-82.59%
4.95
-68.16%
15.53
Net Income From Continuing Operation Net Minority Interest
37.03
+4201.05%
0.86
-82.59%
4.95
-68.16%
15.53
Net Income From Continuing And Discontinued Operation
37.03
+4201.05%
0.86
-82.59%
4.95
-68.16%
15.53
Net Income Continuous Operations
37.03
+4201.05%
0.86
-82.59%
4.95
-68.16%
15.53
Normalized Income
45.84
+142.87%
18.87
+281.67%
4.95
-68.16%
15.53
Net Income Common Stockholders
20.02
+2236.82%
-0.94
-118.95%
4.95
-68.16%
15.53
Otherunder Preferred Stock Dividend
6.18
+1400.00%
0.41
0.00
0.00
Diluted EPS
0.15
+1600.00%
-0.01
-125.00%
0.04
-66.67%
0.12
Basic EPS
0.16
+1700.00%
-0.01
-125.00%
0.04
-66.67%
0.12
Basic Average Shares
126.74
-3.75%
131.67
+0.34%
131.23
+0.89%
130.07
Diluted Average Shares
130.25
-1.08%
131.67
-0.81%
132.75
+0.27%
132.38
Diluted NI Availto Com Stockholders
20.02
+2236.82%
-0.94
-118.95%
4.95
-68.16%
15.53
Preferred Stock Dividends
10.83
+681.39%
1.39
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
598.73
+20.25%
497.89
+8.23%
460.02
+2.37%
449.36
Current Assets
362.19
+26.67%
285.94
+27.06%
225.04
+1.09%
222.61
Cash Cash Equivalents And Short Term Investments
93.68
-30.90%
135.57
+30.56%
103.84
+1.33%
102.48
Cash And Cash Equivalents
93.68
-30.90%
135.57
+30.56%
103.84
+1.33%
102.48
Receivables
217.45
+97.93%
109.86
+33.98%
82.00
-8.33%
89.45
Accounts Receivable
217.45
+97.93%
109.86
+33.98%
82.00
-8.33%
89.45
Gross Accounts Receivable
233.54
+95.53%
119.44
+34.41%
88.86
-7.26%
95.81
Allowance For Doubtful Accounts Receivable
-16.09
-68.01%
-9.58
-39.59%
-6.86
-7.83%
-6.36
Inventory
29.63
+13.00%
26.22
-7.20%
28.25
+14.00%
24.78
Raw Materials
14.34
+8.20%
13.25
+2.03%
12.99
+5.75%
12.28
Work In Process
1.26
+37.05%
0.92
+13.95%
0.81
-20.74%
1.02
Finished Goods
14.02
+16.43%
12.04
-16.68%
14.46
+25.93%
11.48
Prepaid Assets
10.96
+29.59%
8.46
+58.56%
5.34
+571.19%
0.80
Restricted Cash
0.65
+12.41%
0.58
+16.47%
0.50
-38.67%
0.81
Assets Held For Sale Current
2.42
0.00
—
—
Other Current Assets
7.39
+40.77%
5.25
+2.56%
5.12
+19.27%
4.29
Total Non Current Assets
236.54
+11.61%
211.94
-9.80%
234.98
+3.63%
226.75
Net PPE
159.46
+26.32%
126.24
-19.26%
156.35
+7.34%
145.66
Gross PPE
247.57
+24.29%
199.19
-13.22%
229.53
+10.11%
208.45
Accumulated Depreciation
-88.11
-20.78%
-72.95
+0.32%
-73.19
-16.54%
-62.80
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.00
-100.00%
13.60
+175.14%
4.94
+0.00%
4.94
Machinery Furniture Equipment
69.23
+9.46%
63.25
-2.07%
64.58
+13.02%
57.15
Construction In Progress
26.74
+22.19%
21.89
-62.95%
59.07
-9.91%
65.56
Other Properties
83.72
+125.61%
37.11
-7.50%
40.12
-7.12%
43.19
Leases
67.87
+7.14%
63.34
+4.15%
60.82
+61.72%
37.61
Goodwill And Other Intangible Assets
37.92
-8.06%
41.24
-7.62%
44.64
-9.92%
49.56
Goodwill
28.77
+0.00%
28.77
+0.00%
28.77
+0.00%
28.77
Other Intangible Assets
9.14
-26.65%
12.47
-21.44%
15.87
-23.66%
20.79
Non Current Deferred Assets
29.96
-24.07%
39.46
+40.93%
28.00
-6.70%
30.01
Non Current Deferred Taxes Assets
29.96
-24.07%
39.46
+40.93%
28.00
-6.70%
30.01
Other Non Current Assets
9.20
+83.88%
5.00
-16.44%
5.99
+294.08%
1.52
Total Liabilities Net Minority Interest
164.81
+46.41%
112.57
-37.93%
181.36
-1.27%
183.69
Current Liabilities
100.12
+29.23%
77.48
-3.77%
80.51
+7.31%
75.02
Payables And Accrued Expenses
33.65
-21.89%
43.08
+3.99%
41.42
+1.68%
40.74
Payables
31.95
-3.76%
33.20
-0.97%
33.52
-4.10%
34.95
Accounts Payable
31.95
+10.51%
28.91
-5.90%
30.72
-4.97%
32.33
Current Accrued Expenses
1.70
-82.82%
9.88
+25.06%
7.90
+36.62%
5.78
Pensionand Other Post Retirement Benefit Plans Current
42.71
+79.20%
23.84
+30.34%
18.29
+6.86%
17.11
Total Tax Payable
0.00
-100.00%
4.29
+53.13%
2.80
+6.63%
2.62
Current Debt And Capital Lease Obligation
18.64
+104.56%
9.11
-53.77%
19.71
+21.33%
16.25
Current Debt
—
—
5.49
+20.89%
4.54
Other Current Borrowings
—
—
5.49
+20.89%
4.54
Current Capital Lease Obligation
18.64
+104.56%
9.11
-35.94%
14.22
+21.50%
11.71
Current Deferred Liabilities
3.86
0.00
—
0.00
Current Deferred Revenue
3.86
0.00
—
—
Other Current Liabilities
1.26
-13.10%
1.45
+33.39%
1.09
+17.39%
0.93
Total Non Current Liabilities Net Minority Interest
64.69
+84.33%
35.09
-65.20%
100.85
-7.19%
108.67
Long Term Debt And Capital Lease Obligation
63.49
+85.66%
34.20
-65.68%
99.64
-7.35%
107.55
Long Term Debt
—
—
60.74
-8.28%
66.23
Long Term Capital Lease Obligation
63.49
+85.66%
34.20
-12.07%
38.90
-5.86%
41.31
Non Current Deferred Liabilities
—
—
—
—
Other Non Current Liabilities
1.19
+33.45%
0.89
-26.30%
1.21
+8.11%
1.12
Stockholders Equity
433.92
+12.61%
385.32
+38.27%
278.66
+4.89%
265.67
Common Stock Equity
300.13
+14.16%
262.90
-5.66%
278.66
+4.89%
265.67
Capital Stock
133.80
+9.29%
122.43
+941684.62%
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
133.79
+9.29%
122.42
0.00
0.00
Share Issued
127.68
+0.97%
126.46
-4.23%
132.04
+0.30%
131.65
Ordinary Shares Number
126.95
+0.97%
125.73
-4.25%
131.32
+0.30%
130.92
Treasury Shares Number
0.73
+0.00%
0.73
+0.00%
0.73
+0.00%
0.73
Additional Paid In Capital
303.19
+0.07%
302.99
-5.20%
319.62
+2.79%
310.96
Retained Earnings
-3.08
+92.33%
-40.11
+2.10%
-40.97
+9.56%
-45.30
Total Equity Gross Minority Interest
433.92
+12.61%
385.32
+38.27%
278.66
+4.89%
265.67
Total Capitalization
433.92
+12.61%
385.32
+13.53%
339.41
+2.26%
331.90
Working Capital
262.06
+25.71%
208.46
+44.23%
144.53
-2.07%
147.59
Invested Capital
300.13
+14.16%
262.90
-23.77%
344.89
+2.51%
336.44
Total Debt
82.14
+89.64%
43.31
-63.71%
119.35
-3.59%
123.79
Capital Lease Obligations
82.14
+89.64%
43.31
-18.46%
53.12
+0.18%
53.02
Net Tangible Assets
396.00
+15.09%
344.08
+47.03%
234.02
+8.29%
216.11
Tangible Book Value
262.21
+18.30%
221.66
-5.28%
234.02
+8.29%
216.11
Preferred Stock Equity
133.79
+9.29%
122.42
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.31
-172.56%
14.21
-54.04%
30.92
+24.37%
24.86
Cash Flow From Continuing Operating Activities
-10.31
-172.56%
14.21
-54.04%
30.92
+24.37%
24.86
Net Income From Continuing Operations
37.03
+4201.05%
0.86
-82.59%
4.95
-68.16%
15.53
Depreciation Amortization Depletion
26.94
+6.16%
25.37
+8.21%
23.45
+30.05%
18.03
Depreciation
23.61
+7.48%
21.97
+18.56%
18.53
+40.94%
13.15
Amortization Cash Flow
3.32
-2.35%
3.40
-30.81%
4.92
+0.72%
4.88
Depreciation And Amortization
26.94
+6.16%
25.37
+8.21%
23.45
+30.05%
18.03
Amortization Of Intangibles
3.32
-2.35%
3.40
-30.81%
4.92
+0.72%
4.88
Other Non Cash Items
15.73
+76.54%
8.91
+10.59%
8.06
-23.88%
10.58
Stock Based Compensation
13.30
+25.71%
10.58
+17.59%
9.00
+37.30%
6.55
Provisionand Write Offof Assets
8.21
+108.56%
3.94
+203.62%
1.30
-27.18%
1.78
Asset Impairment Charge
11.18
-50.99%
22.80
0.00
0.00
Deferred Tax
9.50
+188.63%
-10.72
-632.75%
2.01
+1.62%
1.98
Deferred Income Tax
9.50
+188.63%
-10.72
-632.75%
2.01
+1.62%
1.98
Operating Gains Losses
0.19
-86.13%
1.35
+476.60%
0.23
-94.76%
4.48
Gain Loss On Sale Of PPE
0.19
-83.51%
1.14
+385.11%
0.23
-94.76%
4.48
Change In Working Capital
-132.38
-170.78%
-48.89
-170.51%
-18.07
+46.97%
-34.08
Change In Receivables
-115.80
-264.16%
-31.80
-674.11%
5.54
+163.16%
-8.77
Changes In Account Receivables
-115.80
-264.16%
-31.80
-674.11%
5.54
+163.16%
-8.77
Change In Inventory
-17.91
-188.77%
-6.20
+24.15%
-8.18
+13.08%
-9.41
Change In Prepaid Assets
-0.18
+92.82%
-2.55
+74.80%
-10.12
-2575.93%
-0.38
Change In Payables And Accrued Expense
9.85
+45.07%
6.79
+124.16%
3.03
+135.27%
-8.59
Change In Accrued Expense
10.38
+13.28%
9.16
+192.03%
3.14
+126.48%
-11.85
Change In Payable
-0.53
+77.74%
-2.37
-2096.30%
-0.11
-103.31%
3.26
Change In Account Payable
-0.53
+77.74%
-2.37
-2096.30%
-0.11
-103.31%
3.26
Change In Other Working Capital
-8.49
+39.63%
-14.07
-66.68%
-8.44
-20.45%
-7.01
Change In Other Current Liabilities
0.16
+114.88%
-1.06
-1267.03%
0.09
+26.39%
0.07
Investing Cash Flow
-14.15
-41.06%
-10.03
+58.82%
-24.36
+28.13%
-33.90
Cash Flow From Continuing Investing Activities
-14.15
-41.06%
-10.03
+58.82%
-24.36
+28.13%
-33.90
Net PPE Purchase And Sale
-14.15
-41.06%
-10.03
+58.82%
-24.36
+28.13%
-33.90
Purchase Of PPE
-14.15
-41.06%
-10.03
+58.82%
-24.36
+28.13%
-33.90
Capital Expenditure
-14.15
-41.06%
-10.03
+58.82%
-24.36
+28.13%
-33.90
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Net Intangibles Purchase And Sale
—
—
—
—
Purchase Of Intangibles
—
—
—
—
Financing Cash Flow
-17.36
-162.81%
27.64
+602.03%
-5.50
-150.34%
-2.20
Cash Flow From Continuing Financing Activities
-17.36
-162.81%
27.64
+602.03%
-5.50
-150.34%
-2.20
Net Issuance Payments Of Debt
-1.17
+98.27%
-67.64
-1207.64%
-5.17
-71.69%
-3.01
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
-1.17
+98.27%
-67.64
-1207.64%
-5.17
-71.69%
-3.01
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
-1.17
+98.27%
-67.64
-1207.64%
-5.17
-71.69%
-3.01
Net Long Term Debt Issuance
-1.17
+98.27%
-67.64
-1207.64%
-5.17
-71.69%
-3.01
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
0.00
+100.00%
-25.48
0.00
0.00
Common Stock Payments
0.00
+100.00%
-25.48
0.00
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-25.48
0.00
0.00
Proceeds From Stock Option Exercised
0.16
-87.41%
1.25
0.00
-100.00%
2.07
Net Other Financing Charges
-16.35
-1291.15%
-1.18
-253.92%
-0.33
+73.57%
-1.26
Changes In Cash
-41.82
-231.46%
31.81
+2935.59%
1.05
+109.33%
-11.24
Beginning Cash Position
136.15
+30.49%
104.34
+1.01%
103.29
-9.81%
114.53
End Cash Position
94.33
-30.72%
136.15
+30.49%
104.34
+1.01%
103.29
Free Cash Flow
-24.46
-685.73%
4.18
-36.27%
6.55
+172.50%
-9.04
Interest Paid Supplemental Data
0.00
-100.00%
4.97
-8.57%
5.44
+105.21%
2.65
Income Tax Paid Supplemental Data
5.35
-23.24%
6.96
+128.21%
3.05
+154.12%
1.20
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
0.00
-100.00%
120.69
0.00
0.00
Net Preferred Stock Issuance
0.00
-100.00%
120.69
0.00
0.00
Preferred Stock Issuance
0.00
-100.00%
120.69
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category